Navigation Links
OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
Date:4/9/2009

BOTHELL, WA, and VANCOUVER, April 9 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI), announced today that it has been named the 2009 Life Sciences Company of the Year by LifeSciences British Columbia. This annual award is presented by LifeSciences British Columbia to recognize a local organization that has made outstanding contributions to the development of British Columbia's life sciences industry. This award recognizes a company for execution of business strategies, scientific excellence, leadership and vision and market position/opportunity. The organization also uses this award to increase public awareness and understanding of life sciences in the province.

"We are very pleased to be recognized for this award, especially in light of what was a particularly challenging economic environment in 2008," said Scott Cormack, President and CEO of OncoGenex. "For OncoGenex, 2008 was a tremendously active year as we took measures to prepare for the final stages of clinical development of our lead product candidate, OGX-011, for the treatment of cancer. We released Phase 2 clinical data showing a survival benefit in patients treated with OGX-011 and are working closely with the FDA to develop Phase 3 study designs and protocols defining a registration path for product approval. We also took measures to extend our cash runway, and we have been advancing discussions with potential development partners."

"There is no greater honour than to be recognized by one's peers," added Cormack. "I'd like to thank all the employees at OncoGenex, as this award was earned by each and every one of them through their dedication, hard work and loyalty."

About LifeSciences British Columbia

LifeSciences British Columbia supports and represents the biopharmaceutical, medical device, biopro
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Nuvilex, Inc. (OTCQB: NVLX) – According ... worldwide are living with diabetes, with  that number expected ... global market for diabetes treatments is approximately $500 billion.  ... died from pancreatic cancer.  Pancreatic cancer is the fourth ... the United States , and according ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... , FORT WORTH, Texas , ... Board: WNDM), announced today that it is nearing the completion of its ... first distributor in that country.  Numerous physicians in the nation have ... with its speed and efficacy in the management of diabetic ulcers ...
... , SAN FRANCISCO , Jan. 13 ... fully configurable system that allows users to design and deploy ... and cost of other providers. Leveraging a background of more ... the Clinical Trial industry, endpoint designed PULSE to balance speed ...
... , ROCHESTER, N.Y. , Jan. ... for biomedical research in the U.S. has decelerated and may have even ... today published in the Journal of the American Medical Association . ... began in the 1990,s has ended," said Ray Dorsey , ...
Cached Biology Technology:Wound Management Technologies, Inc. Rapidly Expands Its International Presence 2Wound Management Technologies, Inc. Rapidly Expands Its International Presence 3Wound Management Technologies, Inc. Rapidly Expands Its International Presence 4endpoint Introduces First Fully Configurable IRT System 2Study: Era of Rapid Growth in Biomedical Research Over 2Study: Era of Rapid Growth in Biomedical Research Over 3Study: Era of Rapid Growth in Biomedical Research Over 4Study: Era of Rapid Growth in Biomedical Research Over 5Study: Era of Rapid Growth in Biomedical Research Over 6
(Date:10/15/2014)... our ability to assess the pandemic risk from strains ... we must not allow ourselves to become complacent that ... international consortium of scientists. , Influenza pandemics arise when ... yet to develop widespread immunity – spreads in the ... the past 100 years, the worst of which – ...
(Date:10/15/2014)... Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market releases photos and video ... Square on Monday October 13 th . ... Tunnel and angel investor Mr. Chad A. Verdi ... of NXT-ID thanked his investors and employees "for their work and ...
(Date:10/14/2014)... been millions of years since T. rex ... Ohio University scientists is breathing life back into dinosaurs ... snouts. The research has important implications for how dinosaurs ... enhance the sense of smell and cool their brains. ... University doctoral student Jason Bourke, lead author of the ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... 13, 2012) The blood-brain barrier is essential for maintaining ... and isolating the brain,s specific hormonal and neurotransmitter activity from ... addition to nerve cells, the brain contains glia cells that ... blood-brain boundary is made by glia joined into an envelope ...
... DC - On January 18, 2012, Dr. Peter ... National Homeland Security Research Center in the Office ... Protection Agency, will lead a session titled "National ... national resilience to bioterrorism threats involves maximizing advanced ...
... previously un-named species of horse fly whose appearance is dominated ... honour of American pop diva, Beyonc a member of ... single, Bootylicious. , According to the Australian National Insect Collection ... ( Plinthina ) beyonceae , CSIRO,s Bryan Lessard, ...
Cached Biology News:Brain glia cells increase their DNA content to preserve vital blood-brain barrier 2Fly named in honor of Beyonce 2
Mouse monoclonal [N7519] to NR0B2 ( Abpromise for all tested applications). Antigen: E.coli expressed recombinant full length protein (Human) NR0B2 Entrez Gene ID: 8431 Swiss Protein ID: ...
Rabbit polyclonal to BCA1 ( Abpromise for all tested applications). Antigen: Generated using E.coli expressed mouse BCA1. Entrez GeneID: 10563 SWISS Protein ID: O43927...
PKC Sampler Kit 10 mu g each...
Purified anti-SOCS3...
Biology Products: